Natalizumab: targeting alpha4-integrins in multiple sclerosis.

  title={Natalizumab: targeting alpha4-integrins in multiple sclerosis.},
  author={Britta Engelhardt and Ludwig Kappos},
  journal={Neuro-degenerative diseases},
  volume={5 1},
In 1992, it was shown that monoclonal antibodies blocking alpha(4)-integrins prevent the development of experimental autoimmune encephalomyelitis, an animal model for multiple sclerosis (MS). As alpha(4)beta(1)-integrin was demonstrated to mediate the attachment of immune-competent cells to inflamed brain endothelium in experimental autoimmune encephalomyelitis, the therapeutic effect was attributed to the inhibition of immune cell extravasation and inflammation in the central nervous system… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 70 extracted citations

Human Polyomavirus Reactivation: Disease Pathogenesis and Treatment Approaches

Clinical & developmental immunology • 2013
View 3 Excerpts
Highly Influenced

Identification of MS-specific serum miRNAs in an international multicenter study

Neurology(R) neuroimmunology & neuroinflammation • 2018
View 1 Excerpt

ALCAM (CD166) is involved in extravasation of monocytes rather than T cells across the blood-brain barrier.

Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism • 2017
View 3 Excerpts

Similar Papers

Loading similar papers…